Female CEOs
Health
Pharmaceutical
Editas Medicine
$22.619876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$22.61
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$2.13 (-8.61%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell EDIT and other stocks, options, ETFs, and crypto commission-free!
About
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR); and CRISPR associated protein 9 (Cas9). Read More The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu on September 3, 2013 and is headquartered in Cambridge, MA.
Employees
133
Headquarters
Cambridge, Massachusetts
Founded
2013
Market Cap
1.21B
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
921.66K
High Today
$24.68
Low Today
$22.53
Open Price
$24.63
Volume
502.76K
52 Week High
$41.43
52 Week Low
$17.80
Collections
Female CEOs
Health
Pharmaceutical
Therapy
Medical
Technology
Biotechnology
2016 IPO
News
Yahoo FinanceMar 18
What Do Investors Need To Know About Editas Medicine, Inc.’s (NASDAQ:EDIT) Earnings Outlook?
The latest earnings release Editas Medicine, Inc.’s (NASDAQ:EDIT) announced in December 2018 showed that losses became smaller relative to the prior year’s level as a result of recent tailwinds Below is a brief commentary on my key takeaways on how market analysts predict Editas Medicine’s earnings growth trajectory over the next few years and whether the future looks brighter. Note that I will be looking at net income excluding extraordinary items to get a better understanding of the underlying drivers of ...
The Motley FoolMar 12
3 Stocks That Could Double Your Money
Nearly every week, a stock soars or sinks because of a Wall Street analyst's opinion. If a key analyst thinks a stock has better prospects than it did the previous week, that view often becomes a self-fulfilling prophecy, with the stock jumping. The opposite scenario frequently happens as well. Since analysts' opinions often carry so much weight, which stocks are they most bullish about? Three stocks that Wall Street especially loves right now are Editas Medicine (NASDAQ:EDIT), Nektar Therapeutics (NASDAQ:...
Yahoo FinanceMar 4
Edited Transcript of EDIT earnings conference call or presentation 28-Feb-19 10:00pm GMT
Q4 2018 Editas Medicine Inc Earnings Call Cambridge Mar 4, 2019 (Thomson StreetEvents) -- Edited Transcript of Editas Medicine Inc earnings conference call or presentation Thursday, February 28, 2019 at 10:00:00pm GMT TEXT version of Transcript Scroll to continue with content Ad ================================================================================ Corporate Participants ================================================================================ * Cynthia L. Collins Editas Medicine, I...
Price Paid on Robinhood
19% Lower
Right Now
52 Week Low
$17.80
Average Price Paid
$27.89
52 Week High
$41.43
Earnings
-$0.84
-$0.67
-$0.49
-$0.32
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
—
Actual
Expected May 2, After Hours